JD Supra8h
FDA Directed to Explore Elimination of Food Additive "Loophole"
Secretary Kennedy seeks to enhance FDA's oversight of food additives by eliminating a pathway that allows new ingredients to be introduced into ...
Fierce Pharma10h
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Neurology Advisor11h
FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.
Health Affairs12h
Fosamax Lawsuit: The Importance Of State Duties To Warn Of Drug Dangers
Fosamax further defines the obligation of drug manufacturers to present clear, unambiguous, and accurate information to the ...
STAT12h
Pharmalittle: We’re reading about possible HIV prevention cuts, FDA warning an African drugmaker, and more
The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...
Novartis23h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
American Hospital Association1d
FDA alerts of risk with Calyxo aspiration systems
The Food and Drug Administration March 20 issued an alert on a potentially high-risk issue with Calyxo CVAC Aspiration Systems.
Endocrinology Advisor1d
Baqsimi Approved for Severe Hypoglycemia Treatment in Younger Patients
The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.